ID 111143
Author
Takeuchi, Shinji Kanazawa University
Murayama, Toshinori Kanazawa University
Yoshimura, Kenichi Kanazawa University
Kawakami, Takahiro Kanazawa University
Takahara, Shizuko Kanazawa University
Imai, Yasuhito Kanazawa University
Kuribayashi, Yoshikazu Kanazawa University
Nagase, Katsuhiko Kanazawa University
Goto, Koichi National Cancer Center Hospital East
Nishio, Makoto The Cancer Institute Hospital
Hasegawa, Yoshinori Nagoya University
Satouchi, Miyako Hyogo Cancer Center
Kiura, Katsuyuki Okayama University
Seto, Takashi National Kyusyu Cancer Center
Yano, Seiji Kanazawa University
Keywords
RET fusion gene
alectinib
non-small cell lung cancer
Content Type
Journal Article
Description
Background : The rearranged during transfection (RET) fusion gene was discovered as a driver oncogene in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-positive NSCLC. Methods/Design : RET fusion-positive NSCLC patients treated with at least one regimen of chemotherapy are being recruited. In step 1, alectinib (600 or 450 mg, twice daily) will be administered following a 3+3 design. The primary endpoint is safety. In step 2, alectinib will be administered at the recommended dose (RD) defined by step 1. The primary endpoint is the response rate of RET inhibitor treatment-naïve patients. Conclusion : This is the first study to investigate the safety and preliminary efficacy of alectinib in RET fusion-positive NSCLC patients. If successful, alectinib treatment may lead to substantial and important changes in the management of NSCLC with RET fusion genes.
Journal Title
The Journal of Medical Investigation
ISSN
13496867
13431420
NCID
AA11166929
AA12022913
Publisher
Faculty of Medicine Tokushima University
Volume
64
Issue
3-4
Start Page
317
End Page
320
Sort Key
317
Published Date
2017-08
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher